Robert C Miller

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi request reprint Controversies in clinical trials in proton radiotherapy: the present and the future
    Robert C Miller
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Semin Radiat Oncol 23:127-33. 2013
  2. doi request reprint Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy
    Christopher L Hallemeier
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Clin Oncol 34:567-72. 2011
  3. ncbi request reprint Intraoperative radiotherapy for treatment of locally advanced and recurrent esophageal and gastric adenocarcinomas
    R C Miller
    Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Dis Esophagus 19:487-95. 2006
  4. ncbi request reprint Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience
    Robert C Miller
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN55905, USA
    Int J Radiat Oncol Biol Phys 66:1178-86. 2006
  5. pmc Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4
    Robert C Miller
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 79:1460-6. 2011
  6. doi request reprint Marital status and quality of life in patients with esophageal cancer or Barrett's esophagus: the mayo clinic esophageal adenocarcinoma and Barrett's esophagus registry study
    Robert C Miller
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Dig Dis Sci 55:2860-8. 2010
  7. doi request reprint Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium
    Robert C Miller
    Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Int J Radiat Oncol Biol Phys 75:364-8. 2009
  8. doi request reprint Intraperitoneal treatment for peritoneal mucinous carcinomatosis of appendiceal origin after operative management: long-term follow-up of the Mayo Clinic experience
    David A Schomas
    Department of Radiation Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Ann Surg 249:588-95. 2009
  9. doi request reprint Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience
    Douglas G Gold
    Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Int J Radiat Oncol Biol Phys 75:150-5. 2009
  10. doi request reprint Stereotactic body radiotherapy in the treatment of adrenal metastases
    Kamran A Ahmed
    Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL Department of Radiation Oncology, Mayo Clinic, Rochester, MN Department of Radiation Oncology, Providence Medical Center, Kansas City, Kansas
    Am J Clin Oncol 36:509-13. 2013

Detail Information

Publications60

  1. doi request reprint Controversies in clinical trials in proton radiotherapy: the present and the future
    Robert C Miller
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Semin Radiat Oncol 23:127-33. 2013
    ....
  2. doi request reprint Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy
    Christopher L Hallemeier
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Clin Oncol 34:567-72. 2011
    ..To evaluate preoperative CA 19-9 level as a prognostic factor in patients with resected adenocarcinoma of the pancreas...
  3. ncbi request reprint Intraoperative radiotherapy for treatment of locally advanced and recurrent esophageal and gastric adenocarcinomas
    R C Miller
    Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Dis Esophagus 19:487-95. 2006
    ..For patients with isolated local recurrences, IORT may be effective salvage therapy. However, more effective systemic therapy is needed as a component of treatment...
  4. ncbi request reprint Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience
    Robert C Miller
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN55905, USA
    Int J Radiat Oncol Biol Phys 66:1178-86. 2006
    ..The aim of this study was a retrospective assessment of neurotoxicity in patients with multiple sclerosis (MS) receiving external beam radiotherapy (EBRT) to the brain...
  5. pmc Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4
    Robert C Miller
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 79:1460-6. 2011
    ..A two-arm, double-blind, randomized trial was performed to evaluate the effect of 0.1% mometasone furoate (MMF) on acute skin-related toxicity in patients undergoing breast or chest wall radiotherapy...
  6. doi request reprint Marital status and quality of life in patients with esophageal cancer or Barrett's esophagus: the mayo clinic esophageal adenocarcinoma and Barrett's esophagus registry study
    Robert C Miller
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Dig Dis Sci 55:2860-8. 2010
    ..Patients with esophageal carcinoma (EC) report deficits in quality of life (QOL), depending on the extent of malignant disease and the goals of treatment at the time of QOL measurement...
  7. doi request reprint Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium
    Robert C Miller
    Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Int J Radiat Oncol Biol Phys 75:364-8. 2009
    ..To present an overview of Phase III trials in adjuvant therapy for pancreatic cancer and review outcomes at the Mayo Clinic after adjuvant radiochemotherapy (RT/CT) for resected pancreatic cancer...
  8. doi request reprint Intraperitoneal treatment for peritoneal mucinous carcinomatosis of appendiceal origin after operative management: long-term follow-up of the Mayo Clinic experience
    David A Schomas
    Department of Radiation Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Ann Surg 249:588-95. 2009
    ..To determine prognostic factors and the impact of intraperitoneal (IP) treatment after surgical resection of peritoneal mucinous carcinomatosis (PMC) of appendiceal origin...
  9. doi request reprint Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience
    Douglas G Gold
    Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Int J Radiat Oncol Biol Phys 75:150-5. 2009
    ..To analyze the effect of adjuvant chemoradiotherapy on gallbladder carcinoma...
  10. doi request reprint Stereotactic body radiotherapy in the treatment of adrenal metastases
    Kamran A Ahmed
    Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL Department of Radiation Oncology, Mayo Clinic, Rochester, MN Department of Radiation Oncology, Providence Medical Center, Kansas City, Kansas
    Am J Clin Oncol 36:509-13. 2013
    ..To evaluate the dosimetry, clinical outcomes, and toxicity of patients treated with stereotactic body radiotherapy (SBRT) for adrenal metastases...
  11. doi request reprint A pilot study examining circulating interleukin-6 and transforming growth factor-β levels during pelvic radiation therapy
    Christopher L Hallemeier
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Clin Oncol 36:344-7. 2013
    ..To determine if circulating levels of the inflammatory cytokines interleukin-6 (IL-6) and transforming growth factor-β (TGF-β levels) are elevated during pelvic radiotherapy (RT)...
  12. doi request reprint Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors
    Brandon M Barney
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Clin Oncol 35:537-42. 2012
    ..To present clinical outcomes, early toxicity, and dosimetric constraints for patients undergoing stereotactic body radiation therapy (SBRT) for abdominal or pelvic tumors...
  13. pmc Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival
    James M Donahue
    Division of General Thoracic Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Thorac Surg 87:392-8; discussion 398-9. 2009
    ..Neoadjuvant chemoradiotherapy followed by esophagogastrectomy has become the standard of care for patients with locally advanced esophageal cancer. This report analyzes our experience with this treatment approach...
  14. pmc Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a Phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4)
    Michelle A Neben-Wittich
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 81:397-402. 2011
    ..However, prospectively planned secondary analyses of patient-reported outcomes (PROs), using the Skindex-16 and Skin Toxicity Assessment Tool (STAT), were positive. This study assesses the relationship between PA outcomes and PROs...
  15. doi request reprint The prognostic importance of pathologically involved celiac node metastases in node-positive patients with carcinoma of the distal esophagus or gastroesophageal junction: a surgical series from the Mayo Clinic
    David A Schomas
    Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Dis Esophagus 23:232-9. 2010
    ..Therefore, treatment with curative intent should be considered for fit patients with celiac node disease...
  16. pmc Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993)
    Pamela J Atherton
    Division of Biomedical Statistics and Informatics, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    Support Care Cancer 20:1729-35. 2012
    ..The patient-reported Skindex-16 measures symptoms and perceptions of toxicity. This study was designed to compare information provided by these two measures...
  17. doi request reprint Systemic lupus erythematosus, radiotherapy, and the risk of acute and chronic toxicity: the Mayo Clinic Experience
    Melva E Pinn
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 71:498-506. 2008
    ..To determine the acute and chronic toxic effects of radiotherapy in patients with systemic lupus erythematosus (SLE)...
  18. pmc Phase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: results of North Central Cancer Treatment Group N00CA
    James A Martenson
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 26:5248-53. 2008
    ..To assess the effectiveness of depot octreotide for the prevention of diarrhea during pelvic radiation therapy...
  19. doi request reprint Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005)
    Michele M Corsini
    Department of Radiation Oncology the Division of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 26:3511-6. 2008
    ..To determine prognostic factors and impact of adjuvant chemotherapy (CT) and radiotherapy (RT) on overall survival (OS) after resection of pancreatic adenocarcinoma...
  20. doi request reprint Assessment of patient-reported measures of bowel function before and after pelvic radiotherapy: an ancillary study of the North Central Cancer Treatment Group study N00CA
    Pamela J Atherton
    Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA
    Support Care Cancer 21:1193-9. 2013
    ..The Bowel Function Questionnaire (BFQ) has been used in clinical trials to assess symptoms during and after pelvic radiotherapy (RT). This study evaluated the importance of symptoms in the BFQ from a patient perspective...
  21. doi request reprint Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT)
    Brandon M Barney
    Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Int J Radiat Oncol Biol Phys 87:73-80. 2013
    ..We explored the incidence of serious bowel injury (SBI) in patients treated with SBRT with or without vascular endothelial growth factor inhibitor (VEGFI) therapy...
  22. doi request reprint Evidence-based guidelines for adjuvant therapy for resected adenocarcinoma of the pancreas
    Matthew J Iott
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin J Oncol Nurs 12:599-605. 2008
    ....
  23. doi request reprint Early pulmonary toxicity following lung stereotactic body radiation therapy delivered in consecutive daily fractions
    Michael C Stauder
    Department of Radiation Oncology, Mayo Clinic, Rochester, USA
    Radiother Oncol 99:166-71. 2011
    ..Identify the incidence of early pulmonary toxicity in a cohort of patients treated with lung stereotactic body radiation therapy (SBRT) on consecutive treatment days...
  24. doi request reprint Stereotactic body radiation therapy in spinal metastases
    Kamran A Ahmed
    Mayo Medical School, College of Medicine, Mayo Clinic, Rochester, MN, USA
    Int J Radiat Oncol Biol Phys 82:e803-9. 2012
    ..Based on reports of safety and efficacy, stereotactic body radiotherapy (SBRT) for treatment of malignant spinal tumors was initiated at our institution. We report prospective results of this population at Mayo Clinic...
  25. pmc The clinical case for proton beam therapy
    Robert L Foote
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Radiat Oncol 7:174. 2012
    ..We review the clinical case for proton beam therapy. SUMMARY SENTENCE: Proton beam therapy is a technically advanced and promising form of radiation therapy...
  26. ncbi request reprint Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience
    Sumita Bhatia
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 66:514-9. 2006
    ..To determine the effects of adjuvant radiotherapy and chemotherapy for carcinoma of the ampulla of Vater...
  27. pmc Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study
    Amol K Narang
    Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Radiat Oncol 6:126. 2011
    ..We combined the experience of two institutions to better delineate which patients may benefit from adjuvant chemoradiation...
  28. ncbi request reprint Chronic toxicity risk after radiotherapy for patients with systemic sclerosis (systemic scleroderma) or systemic lupus erythematosus: association with connective tissue disorder severity
    Douglas G Gold
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Radiother Oncol 87:127-31. 2008
    ..Building on our prior experience, we postulated that disease severity, as measured by the number of organ systems involved, may predict chronic radiation toxicity risk...
  29. doi request reprint Proton beam radiotherapy versus three-dimensional conformal stereotactic body radiotherapy in primary peripheral, early-stage non-small-cell lung carcinoma: a comparative dosimetric analysis
    O Kenneth Macdonald
    Department of Radiation Oncology, Mayo Clinic, 200 1st Street S W, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 75:950-8. 2009
    ..We analyzed the dosimetric differences between PT and SBRT in treating primary peripheral early-stage non-small-cell lung cancer...
  30. doi request reprint Combined modality therapy including intraoperative electron irradiation for locally recurrent colorectal cancer
    Michael G Haddock
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 79:143-50. 2011
    ..To evaluate survival, relapse patterns, and prognostic factors in patients with colorectal cancer relapse treated with curative-intent therapy, including intraoperative electron radiation therapy (IOERT)...
  31. pmc Acute and late toxicities of radiotherapy for patients with discoid lupus erythematosus: a retrospective case-control study
    Ajaykumar B Patel
    Department of Radiation Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Radiat Oncol 7:22. 2012
    ..The purpose of this study was to evaluate acute and late toxicities of radiotherapy for patients with discoid lupus erythematosus (DLE)...
  32. pmc Incidence of brain metastasis in patients with esophageal carcinoma
    Ron S Smith
    Department of Radiation Oncology, Andreas Cancer Center Mayo Health System, Mankato, MN 56002, USA
    World J Gastroenterol 17:2407-10. 2011
    ..To determine the incidence of brain metastasis in a contemporary group of patients with carcinoma of the esophagus...
  33. doi request reprint Cumulative morbidity and late mortality in long-term survivors of exocrine pancreas cancer
    Nisha L Jacobs
    Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Gastrointest Cancer 40:46-50. 2009
    ..As a result, few studies have focused on these patients' cumulative, cancer-related morbidity and late mortality. This descriptive study was undertaken to explore such issues...
  34. pmc Testicular cancer survivorship: research strategies and recommendations
    Lois B Travis
    Department of Radiation Oncology, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Natl Cancer Inst 102:1114-30. 2010
    ..Just as testicular cancer once served as the paradigm of a curable malignancy, comprehensive follow-up studies of testicular cancer survivors can pioneer new methodologies in survivorship research for all adult-onset cancer...
  35. doi request reprint Multimodality therapy including salvage surgical resection and intraoperative radiotherapy for patients with squamous-cell carcinoma of the anus with residual or recurrent disease after primary chemoradiotherapy
    Christopher L Hallemeier
    1Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 2Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas 3Department of Colon and Rectal Surgery, Mayo Clinic, Rochester, Minnesota
    Dis Colon Rectum 57:442-8. 2014
    ..Patients with unresectable or borderline unresectable disease have poor outcomes, thus adjunctive treatments should be explored...
  36. ncbi request reprint Radiotherapy for malignancy in patients with scleroderma: The Mayo Clinic experience
    Douglas G Gold
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 67:559-67. 2007
    ..To determine the frequency of acute and chronic adverse effects in patients with scleroderma who receive radiotherapy for treatment of cancer...
  37. ncbi request reprint Intraoperative electron-beam radiotherapy and ureteral obstruction
    Robert C Miller
    Division of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 64:792-8. 2006
    ..To quantify the risk of ureteral obstruction (UO) after intraoperative electron-beam radiotherapy (IOERT)...
  38. pmc Intensity-modulated radiotherapy for squamous cell carcinoma of the anal canal: efficacy of a low daily dose to clinically negative regions
    Jason A Call
    Department of Radiation Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Radiat Oncol 6:134. 2011
    ..We aimed to assess outcomes of patients with anal cancer who underwent intensity-modulated radiotherapy (IMRT) and received less than 1.80 Gy/day...
  39. ncbi request reprint Phase III study of pentosanpolysulfate (PPS) in treatment of gastrointestinal tract sequelae of radiotherapy
    Miljenko V Pilepich
    Department of Radiation Oncology, UCLA, Los Angeles, CA, USA
    Am J Clin Oncol 29:132-7. 2006
    ..To evaluate the effectiveness of pentosanpolysulfate (PPS) in the treatment of gastrointestinal tract sequelae of radiotherapy...
  40. ncbi request reprint Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial
    Robert C Miller
    North Central Cancer Treatment Group, Coordinating Center, Rochester, MN, USA
    Int J Radiat Oncol Biol Phys 54:409-13. 2002
    ..Toxicity from a previously reported randomized clinical trial was analyzed to quantify the difference in this risk. Additionally, the persistence of diarrhea after RT was analyzed...
  41. pmc Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma
    Brandon M Barney
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA
    Radiat Oncol 7:67. 2012
    ..To report single-institutional clinical outcomes and toxicity with SBRT for cholangiocarcinoma...
  42. ncbi request reprint Informed consent in advanced laryngeal cancer
    Robert L Foote
    Department of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Head Neck 29:230-5. 2007
    ..This study was designed to evaluate the relationship between the informed consent process and the treatment received by patients with advanced laryngeal cancer...
  43. ncbi request reprint A historical prospective cohort study of carotid artery stenosis after radiotherapy for head and neck malignancies
    Paul D Brown
    Division of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 63:1361-7. 2005
    ..To determine carotid artery stenosis incidence after radiotherapy for head-and-neck neoplasms...
  44. pmc Radiation-induced optic neuritis after pituitary adenoma radiosurgery in a patient with multiple sclerosis: case report
    Thomas B Daniels
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Neurooncol 93:263-7. 2009
    ..To describe a rare case of optic neuritis onset after Gamma Knife stereotactic radiosurgery...
  45. ncbi request reprint Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer
    Jann N Sarkaria
    Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Thorac Oncol 2:751-7. 2007
    ..The safety and tolerability of sirolimus combined with thoracic radiation and cisplatin was evaluated in patients with lung cancer. In parallel, the effects of sirolimus were studied in a murine model of radiation pneumonitis...
  46. ncbi request reprint Incidence of radiation pneumonitis after thoracic irradiation: Dose-volume correlates
    John M Schallenkamp
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 67:410-6. 2007
    ..To define clinical and dosimetric parameters correlated with the risk of clinically relevant radiation pneumonitis (RP) after thoracic radiotherapy...
  47. ncbi request reprint Incidence and outcomes of chemotherapy and radiation in morbidly obese patients with locally advanced lung and esophageal cancers: a single-institution experience
    Krishna Patel
    Department of Oncology and Cancer Education Program, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Control 21:63-6. 2014
    ..This guideline does not address dosages for patients who are morbidly obese (body mass index ≥ 40) and receiving concomitant chemotherapy and radiation...
  48. pmc Radiotherapy for marginally resected, unresectable or recurrent giant cell tumor of the bone: a rare cancer network study
    Sumita Bhatia
    Mayo Clinic, Rochester, MN, USA
    Rare Tumors 3:e48. 2011
    ..This study reports a large published experience in the treatment of GCToB with radiotherapy. Radiotherapy can provide excellent local control for incompletely resected, unresectable or recurrent GCToB with acceptable morbidity...
  49. pmc Adjuvant chemoradiotherapy for resected pancreas cancer
    Matthew Iott
    Matthew Iott, Michelle Neben Wittich, Robert C Miller, Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, United States
    World J Gastrointest Surg 2:373-80. 2010
    ..The debate will likely continue. Current practice should be based on the weight of evidence available at this time, which is in favor of adjuvant chemotherapy with chemoradiotherapy...
  50. ncbi request reprint Curing patients with locally advanced esophageal cancer: an update on multimodality therapy
    K P McKian
    Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Dis Esophagus 19:448-53. 2006
    ..This review discusses recent studies in this field and outlines promising versus less promising therapeutic strategies...
  51. ncbi request reprint Non-traumatic vertebral fractures in patients with locally advanced esophageal cancer: a previously unreported, unrecognized problem
    H McKean
    Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Dis Esophagus 20:102-6. 2007
    ..If confirmed, future studies should focus on identifying risk factors and optimal strategies for the prevention and treatment of vertebral fractures in patients with esophageal cancer...
  52. pmc Impact of endoscopic ultrasonography and physician specialty on the management of patients with esophagus cancer
    A Gines
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Dis Esophagus 21:241-50. 2008
    ..With respect to the optimal treatment for each patient, agreement among physicians incrementally increases with endoscopic ultrasound results. Specialty training appears to influence therapeutic decision-making behavior...
  53. ncbi request reprint Lung V20 measurements: In regard to Seppenwoolde et al. (Int J Radiat Oncol Biol Phys 2003;55:724-735), and Tsujino et al. (Int J Radiat Oncol Biol Phys 2003;56:1208-1209)
    Yolanda I Garces
    Int J Radiat Oncol Biol Phys 58:1636; author reply 1636-7. 2004
  54. ncbi request reprint Primary spinal epidural lymphoma: patients' profile, outcome, and prognostic factors: a multicenter Rare Cancer Network study
    Virginie Monnard
    Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Int J Radiat Oncol Biol Phys 65:817-23. 2006
    ..To assess the clinical profile, treatment outcome, and prognostic factors in primary spinal epidural lymphoma (PSEL)...
  55. ncbi request reprint Outcome and prognostic factors in cerebellar glioblastoma multiforme in adults: a retrospective study from the Rare Cancer Network
    Damien C Weber
    University Hospital of Geneva, Geneva, Switzerland
    Int J Radiat Oncol Biol Phys 66:179-86. 2006
    ..The aim of this study was to assess the outcome in patients with cerebellar glioblastoma (GBM) treated in 15 institutions of the Rare Cancer Network...
  56. ncbi request reprint Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network
    Aurelius Omlin
    Department of Radiation Oncology, University of Bern, Inselspital, Bern, Switzerland
    Lancet Oncol 7:652-6. 2006
    ..Outcome data in young women with ductal carcinoma in situ (DCIS) are rare. The benefits of boost radiotherapy in this group are also unknown. We aimed to assess the effect of boost radiotherapy in young patients with DCIS...
  57. ncbi request reprint Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN)
    Hadassah Goldberg
    Division of Oncology, Rambam Health Care Campus and Rappaport Faculty of Medicine, Technion, Haifa, Israel
    Gynecol Oncol 108:298-305. 2008
    ..Uterine papillary serous carcinoma (UPSC) is a rare subtype of endometrial carcinoma, characterized by a poor outcome. We sought to better analyze the effect of surgery and adjuvant therapies on this disease...
  58. ncbi request reprint Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience
    Joseph K Salama
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA
    J Clin Oncol 25:4581-6. 2007
    ..To report a multicenter experience treating anal canal cancer patients with concurrent chemotherapy and intensity-modulated radiation therapy (IMRT)...
  59. ncbi request reprint Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy
    Loren K Mell
    Department of Radiation and Cellular Oncology, University of Chicago and University of Illinois at Chicago, Chicago, IL 60637, USA
    Int J Radiat Oncol Biol Phys 70:1431-7. 2008
    ....
  60. ncbi request reprint Treatment results of 165 pediatric patients with non-metastatic nasopharyngeal carcinoma: a Rare Cancer Network study
    Enis Ozyar
    Hacettepe University, Oncology Institute, Ankara, Turkey
    Radiother Oncol 81:39-46. 2006
    ..This Rare Cancer Network (RCN) study was performed in pediatric nasopharyngeal carcinoma (PNPC) patients to evaluate the optimal dose of radiotherapy and to determine prognostic factors...